Fig. 2

a qRT–PCR analysis of the expression of NORAD in radioresistant ESCC cells (KYSE-150R and TE-1R) and their parental cells (KYSE-150 and TE-1). b qRT–PCR analysis of NORAD expression in KYSE-150 cells treated with 8 Gy of X-ray radiation, cisplatin or doxorubicin. c Subcellular fractionation followed by qRT–PCR analysis of NORAD expression in KYSE-150 and TE-1 cells (GAPDH was used as a cytoplasmic control). d-e FISH results for NORAD expression in KYSE-150 and TE-1 cells before (d) and after (e) 8 Gy X-ray treatment. The scale bar represents 25 μm. f qRT–PCR measurement of NORAD expression in ESCC tissues and adjacent normal tissues. g qRT–PCR measurement of NORAD expression in ESCC tissues from patients with local recurrence and nonrecurrence. h ROC curve for predicting ESCC local recurrence based on NORAD expression. AUC = 0.763 (0.601–0.924; p < 0.05). (qRT–PCR results were quantified relative to GAPDH, n = 3 technical replicates, *P < 0.05, **P < 0.01, *** P < 0.001, ****P < 0.0001)